Intravitreal Dexamethasone Implant with Plasma Autoantibody Monitoring for Cancer-associated Retinopathy
Min Seok Kim, Hye Kyoung Hong, Kyu Hyung Park, Se Joon Woo
Korean J Ophthalmol. 2019;33(3):298-300.   Published online 2019 Jun 4     DOI: https://doi.org/10.3341/kjo.2018.0091
Citations to this article as recorded by Crossref logo
Intravitreal Dexamethasone Implant as a Sustained Release Drug Delivery Device for the Treatment of Ocular Diseases: A Comprehensive Review of the Literature
Claudio Iovino, Rodolfo Mastropasqua, Marco Lupidi, Daniela Bacherini, Marco Pellegrini, Federico Bernabei, Enrico Borrelli, Riccardo Sacconi, Adriano Carnevali, Rossella D’Aloisio, Alessio Cerquaglia, Lucia Finocchio, Andrea Govetto, Stefano Erba, Giacin
Pharmaceutics.2020; 12(8): 703.     CrossRef
Cancer is associated with a 2.7 higher risk for intravitreal injection therapy in patients with age‐related, diabetic, or vascular occlusive macular edema
Sirpa Loukovaara, Jari Haukka
Acta Ophthalmologica.2020;[Epub]     CrossRef
An update on autoimmune retinopathy
Parthopratim Dutta Majumder, Alessandro Marchese, Francesco Pichi, Itika Garg, Aniruddha Agarwal
Indian Journal of Ophthalmology.2020; 68(9): 1829.     CrossRef